https://scholars.lib.ntu.edu.tw/handle/123456789/577173
標題: | Transdermal drug delivery systems for fighting common viral infectious diseases | 作者: | Wang F.-Y Chen Y Huang Y.-Y Cheng C.-M. YI-YOU HUANG |
關鍵字: | Microneedle vaccine; Microneedles; Transdermal drug delivery; Transdermal patches; Transdermal sampling; Viral infection | 公開日期: | 2021 | 來源出版物: | Drug Delivery and Translational Research | 摘要: | Transdermal drug delivery systems (TDDS) have many advantages and represent an excellent alternative to oral delivery and hypodermic injections. TDDS are more convenient and less invasive tools for disease and viral infection treatment, prevention, detection, and surveillance. The emerging development of microneedles for TDDS has facilitated improved skin barrier penetration for the delivery of macromolecules or hydrophilic drugs. Microneedle TDDS patches can be fabricated to deliver virus vaccines and potentially provide a viable alternative vaccine modality that offers improved immunogenicity, thermostability, simplicity, safety, and compliance as well as sharp-waste reduction, increased cost-effectiveness, and the capacity for self-administration, which could improve vaccine distribution. These advantages make TDDS-based vaccine delivery an especially well-suited option for treatment of widespread viral infectious diseases including pandemics. Because microneedle-based bioassays employ transdermal extraction of interstitial fluid or blood, they can be used as a minimally invasive approach for surveying disease markers and providing point-of-care (POC) diagnostics. For cutaneous viral infections, TDDS can provide localized treatment with high specificity and less systemic toxicity. In summary, TDDS, especially those that employ microneedles, possess special attributes that can be leveraged to reduce morbidity and mortality from viral infectious diseases. In this regard, they may have considerable positive impact as a modality for improving global health. In this article, we introduce the possible role and summarize the current literature regarding TDDS applications for fighting common cutaneous or systemic viral infectious diseases, including herpes simplex, varicella or herpes zoster, warts, influenza, measles, and COVID-19. Graphical abstract: [Figure not available: see fulltext.]. ? 2021, Controlled Release Society. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106422544&doi=10.1007%2fs13346-021-01004-6&partnerID=40&md5=a38213f684676e9b217e18097ef0a4b0 https://scholars.lib.ntu.edu.tw/handle/123456789/577173 |
ISSN: | 2190393X | DOI: | 10.1007/s13346-021-01004-6 | SDG/關鍵字: | virus vaccine; antivirus agent; Article; bioassay; chickenpox; classification; coronavirus disease 2019; device safety; disease marker; drug delivery system; drug self administration; global health; herpes simplex; herpes zoster; human; hydrophilicity; immunogenicity; influenza; interstitial fluid; local therapy; macromolecule; measles; minimally invasive procedure; morbidity; mortality; pandemic; point of care testing; skin penetration; thermostability; vaccination; vaccine immunogenicity; verruca vulgaris; virus infection; animal; communicable disease; cutaneous drug administration; immunology; metabolism; microinjection; procedures; Administration, Cutaneous; Animals; Antiviral Agents; Communicable Diseases; COVID-19; Drug Delivery Systems; Humans; Microinjections |
顯示於: | 醫學工程學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。